Trump tightens pressure on pharmaceuticals, eases part of the metals burden, and signals a more targeted tariff strategy for US supply chains
💊 On the first anniversary of “Liberation Day,” Trump signed a new tariff package with a more selective approach after the earlier broad-based tariff model was struck down by the court. This time, the main objective is to force drugmakers either to cut prices for the US market or speed up plans to move production back onshore.
🏭 For patented pharmaceuticals, tariffs could reach as high as 100% if companies refuse to comply, while firms that commit to shifting part of their production to the US would face lower rates and receive a few months to adjust. On the other side, tariffs on many derivative metal products were reduced, suggesting Washington still wants to protect domestic metals production without putting too much pressure on industries that rely heavily on those inputs.
📈 The short-term effect leans supportive for US steel while increasing pressure on imported drugmakers, but the trade-off is that cost pressure still lingers for manufacturing, infrastructure, and medicine prices. In essence, this marks a shift from “tariffs everywhere” to “tariffs where it matters,” preserving the America First stance while trying to reduce the side effects on the domestic economy.